Built financial models and valuation frameworks for large-scale infrastructure projects, equipping executives with data-driven recommendations that optimized capital allocation and improved ROI.
Introduced an integrated cost-control and inventory system that reduced delivery errors by 25%, improved working capital efficiency, and strengthened reporting accuracy.
Redesigned project and dispatch workflows, cutting lead times by 20% and driving measurable cost savings while ensuring consistent on-time delivery.
Conducted feasibility and financial assessments for major water infrastructure initiatives in partnership with public stakeholders, aligning technical execution with economic viability.
Delivered market and client analyses that secured four large-scale construction projects, expanding the company's portfolio and strengthening revenue growth.
Developed executive-ready dashboards and reporting tools, integrating operational KPIs with financial outcomes to enhance transparency and support strategic decision-making.
Education
Master of Science - Banking And Finance
Queen Mary University of London
London - UK
04.2001 -
Bachelor of Science - Banking And Finance
Lebanese American University
Byblos
04.2001 -
Skills
Advanced Excel
Accounts receivable
Bloomberg Terminal
Problem-Solving & Analytical Thinking
Presentation & Pitching Skills
Quantitative & Statistical Analysis
Financial Modelling & Forecasting
Discounted Cash Flow (DCF) Valuation
Relative Valuation & Multiples Analysis
Market Research & Competitive Analysis (SWOT, PESTEL, Porter’s Five Forces)
Strategic Planning & Scenario Analysis
Stakeholder Engagement & Client Communication
Accomplishments
Queen Mary MSc Investment Fund (QUMMIF) – London, UK
Competed against 22 teams in a multi-phase investment competition, submitting a 20-page equity research report on Novo Nordisk A/S and ranking in the top 10 for presentation.
Produced detailed financial analysis incorporating DCF valuation, multiples benchmarking, and strategic frameworks (SWOT, PESTEL, Porter's Five Forces) to support a “Buy” recommendation.
Delivered a 20-minute presentation to a panel of academics, finance professionals, and industry judges, articulating Novo Nordisk's valuation, growth potential, and market positioning.
Secured 4th place overall, with Novo Nordisk selected as one of five companies added to the £40,000 QUMMIF portfolio.
Conducted a DCF using a 6.09% WACC and 2% terminal growth rate, projecting an intrinsic value of kr1,002, supported by scenario and sensitivity analysis.
Finance Trading Programme (FTP) – London, UK
Completed a structured programme on financial markets, trading strategies, and risk management, covering 12 advanced modules.
Developed expertise in technical analysis, credit derivatives and swaps, and quantitative trading strategies through applied training.
Participated in simulated trading sessions using industry-standard platforms, with hands-on experience in equities, fixed income, and derivatives.
Enhanced understanding of macroeconomic cycles, central bank policies, and capital markets through case studies and practical exercises.